

Eosinophilic Esophagitis Toolkit

Epidemiology

Resource	Address
Arias Á, Lucendo AJ. Incidence and prevalence of eosinophilic oesophagitis increase continuously in adults and children in Central Spain: A 12-year population-based study. <i>Dig Liver Dis.</i> 2019;51(1):55-62. doi:10.1016/j.dld.2018.07.016	https://pubmed.ncbi.nlm.nih.gov/30115573/
Assa'ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. <i>Gastroenterology.</i> 2011;141(5):1593-1604. doi:10.1053/j.gastro.2011.07.044	https://pubmed.ncbi.nlm.nih.gov/21835135/
Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). <i>Am J Gastroenterol.</i> 2013;108(5):679-693. doi:10.1038/ajg.2013.71	https://pubmed.ncbi.nlm.nih.gov/23567357/
Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. <i>Gastroenterology.</i> 2018;154(2):319-332.e3. doi:10.1053/j.gastro.2017.06.067	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794619/
Dellon ES, Kim HP, Sperry SL, Rybnicek DA, Woosley JT, Shaheen NJ. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. <i>Gastrointest Endosc.</i> 2014;79(4):577-585.e4. doi:10.1016/j.gie.2013.10.027	https://pubmed.ncbi.nlm.nih.gov/24275329/
Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology.</i> 2018;155(4):1022-1033.e10. doi:10.1053/j.gastro.2018.07.009	https://pubmed.ncbi.nlm.nih.gov/30009819/
Dellon ES, Lucendo AJ, Schlag C, et al. Fluticasone propionate orally disintegrating tablet (APT-1011) for eosinophilic esophagitis: Randomized controlled trial. <i>Clin Gastroenterol Hepatol.</i> 2022;20(11):2485-2494.e15. doi:10.1016/j.cgh.2022.02.013	https://pubmed.ncbi.nlm.nih.gov/35181572/
Dellon ES, Woosley JT, Arrington A, et al. Rapid recurrence of eosinophilic esophagitis activity after successful treatment in the observation phase of a randomized, double-blind, double-dummy trial. <i>Clin Gastroenterol Hepatol.</i> 2020;18(7):1483-1492.e2. doi:10.1016/j.cgh.2019.08.050	https://pubmed.ncbi.nlm.nih.gov/31499249/
Diny NL, Rose NR, Čiháková D. Eosinophils in autoimmune diseases. <i>Front Immunol.</i> 2017;8:484. doi:10.3389/fimmu.2017.00484	https://pubmed.ncbi.nlm.nih.gov/28496445/
Dispenza MC, Bochner BS. Diagnosis and novel approaches to the treatment of hypereosinophilic syndromes. <i>Curr Hematol Malig Rep.</i> 2018;13(3):191-201. doi:10.1007/s11899-018-0448-8	https://pubmed.ncbi.nlm.nih.gov/29680938/

Doerfler B, Bryce P, Hirano I, Gonsalves N. Practical approach to implementing dietary therapy in adults with eosinophilic esophagitis: The Chicago experience. <i>Dis Esophagus</i> . 2015;28(1):42-58. doi:10.1111/dote.12175	https://pubmed.ncbi.nlm.nih.gov/24602224/
Doyle AD, Masuda MY, Kita H, Wright BL. Eosinophils in eosinophilic esophagitis: The road to fibrostenosis is paved with good intentions. <i>Front Immunol</i> . 2020;11:603295. doi:10.3389/fimmu.2020.603295	https://www.frontiersin.org/articles/10.3389/fimmu.2020.603295/full
Dupixent® (dupilumab). Prescribing information. Regeneron Pharmaceuticals, Inc; 2022.	https://www.regeneron.com/downloads/dupixent_fpi.pdf
Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: A systematic review and consensus recommendations for diagnosis and treatment. <i>Gastroenterology</i> . 2007;133(4):1342-1363. doi:10.1053/j.gastro.2007.08.017	https://pubmed.ncbi.nlm.nih.gov/17919504/
Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. <i>Expert Rev Clin Immunol</i> . 2017;13(5):425-437. doi:10.1080/1744666X.2017.1298443	https://pubmed.ncbi.nlm.nih.gov/28277826/
Gonsalves N, Yang GY, Doerfler B, Ritz S, Ditto AM, Hirano I. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. <i>Gastroenterology</i> . 2012;142(7):1451-1459.e1. doi:10.1053/j.gastro.2012.03.001	https://pubmed.ncbi.nlm.nih.gov/22391333/
Greuter T, Bussmann C, Safroneeva E, et al. Long-term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: Development and evaluation of a therapeutic concept. <i>Am J Gastroenterol</i> . 2017;112(10):1527-1535. doi:10.1038/ajg.2017.202	https://pubmed.ncbi.nlm.nih.gov/28719593/
Harb H, Chatila TA. Mechanisms of dupilumab. <i>Clin Exp Allergy</i> . 2020;50(1):5-14. doi:10.1111/cea.13491	https://pubmed.ncbi.nlm.nih.gov/31505066/
Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. <i>Gastroenterology</i> . 2020;158(6):1776-1786. doi:10.1053/j.gastro.2020.02.038	https://www.gastrojournal.org/article/S0016-5085(20)30265-1/fulltext
Hirano I, Collins MH, Assouline-Dayyan Y, et al. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. <i>Gastroenterology</i> . 2019;156(3):592-603.e10. doi:10.1053/j.gastro.2018.10.051	https://pubmed.ncbi.nlm.nih.gov/30395812/
Hirano I, Collins MH, Katzka DA, et al. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: Results from a phase 3 trial <i>Clin Gastroenterol Hepatol</i> . 2022;20(3):525-534.e10. doi:10.1016/j.cgh.2021.04.022	https://pubmed.ncbi.nlm.nih.gov/33887475/

<p>Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. <i>Gastroenterology</i>. 2020;158(1):111-122.e10. doi:10.1053/j.gastro.2019.09.042</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31593702/</p>
<p>Hirano I, Furuta GT. Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis. <i>Gastroenterology</i>. 2020;158(4):840-851. doi:10.1053/j.gastro.2019.09.052</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31836530/</p>
<p>Kliwer KL, Sun Q, Fei L, et al. <i>Comparing Two Restrictive Diets for Treating Eosinophilic Esophagitis in Children</i>. Patient-Centered Outcomes Research Institute (PCORI); 2020. doi:10.25302/04.2020.CER.140311593</p>	<p>https://www.pcori.org/sites/default/files/Rothenberg237-Final-Research-Report.pdf</p>
<p>Kliwer K, Gonsalves N, Dellon ES, et al. Efficacy of one-food versus six-food elimination diet for treatment of eosinophilic esophagitis in adults: Results from the multicenter randomized controlled SOFEED trial. <i>Gastroenterology</i>. 2021;160(6 suppl):S109-S110. doi:10.1016/S0016-5085(21)01009-X</p>	<p>https://www.gastrojournal.org/article/S0016-5085(21)01009-X/pdf</p>
<p>Laserna-Mendieta EJ, Casabona S, Guagnozzi D, et al. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: Results from the EoE connect registry. <i>Aliment Pharmacol Ther</i>. 2020;52(5):798-807. doi:10.1111/apt.15957</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32677040/</p>
<p>Mohammad AA, Wu SZ, Ibrahim O, et al. Prevalence of atopic comorbidities in eosinophilic esophagitis: A case-control study of 449 patients. <i>J Am Acad Dermatol</i>. 2017;76(3):559-560. doi:10.1016/j.jaad.2016.08.068</p>	<p>https://pubmed.ncbi.nlm.nih.gov/28212761/</p>
<p>Molina-Infante J, Lucendo AJ. Dietary therapy for eosinophilic esophagitis. <i>J Allergy Clin Immunol</i>. 2018;142(1):41-47. doi:10.1016/j.jaci.2018.02.028</p>	<p>https://pubmed.ncbi.nlm.nih.gov/29522850/</p>
<p>Navarro P, Arias Á, Arias-González L, Laserna-Mendieta EJ, Ruiz-Ponce M, Lucendo AJ. Systematic review with meta-analysis: The growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. <i>Aliment Pharmacol Ther</i>. 2019;49(9):1116-1125. doi:10.1111/apt.15231</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30887555/</p>
<p>Pégorier S, Wagner LA, Gleich GJ, Pretolani M. Eosinophil-derived cationic proteins activate the synthesis of remodeling factors by airway epithelial cells. <i>J Immunol</i>. 2006;177(7):4861-4869. doi:10.4049/jimmunol.177.7.4861</p>	<p>https://pubmed.ncbi.nlm.nih.gov/16982928/</p>
<p>Pérez-Martínez I, Rodrigo L, Lucendo AJ. Eosinophilic esophagitis: An evidenced-based approach to diagnosis and treatment. <i>Esofagitis eosinofílica: Aproximación al diagnóstico y tratamiento desde la evidencia. Med Clin (Barc)</i>. 2019;152(11):444-449. doi:10.1016/j.medcli.2018.10.022</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30522813/</p>

<p>Rank MA, Sharaf RN, Furuta GT, et al. Technical review on the management of eosinophilic esophagitis: A report from the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. <i>Ann Allergy Asthma Immunol.</i> 2020;124(5):424-440.e17. doi:10.1016/j.anai.2020.03.021</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32336463/</p>
<p>Rank MA, Sharaf RN, Furuta GT, et al. Technical review on the management of eosinophilic esophagitis: A report from the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. <i>Gastroenterology.</i> 2020;158(6):1789-1810.e15. doi:10.1053/j.gastro.2020.02.039</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32359563/</p>
<p>Rothenberg M, Dellon E, Bradenoord A, et al. Dupilumab improves clinical and histologic aspects of disease in adult and adolescent patients with eosinophilic esophagitis at week 24: Results from part B of the 3-part LIBERTY EoE TREET study. <i>J Allergy Clin Immunol.</i> 2022;149(2 suppl):AB312. doi:10.1016/j.jaci.2021.12.003</p>	<p>https://www.jacionline.org/article/S0091-6749(21)01826-1/fulltext</p>
<p>Sanofi. Dupixent® (dupilumab) late-breaking phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old. October 11, 2022.</p>	<p>https://www.sanofi.com/en/media-room/press-releases/2022/2022-10-11-05-00-00-2531406</p>
<p>Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. <i>Gastroenterology.</i> 2013;145(6):1230-1236.e2. doi:10.1053/j.gastro.2013.08.015</p>	<p>https://pubmed.ncbi.nlm.nih.gov/23954315/</p>
<p>Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. <i>N Engl J Med.</i> 2016;375(24):2335-2348. doi:10.1056/NEJMoa1610020</p>	<p>https://pubmed.ncbi.nlm.nih.gov/27690741/</p>
<p>Spergel JM, Brown-Whitehorn TF, Cianferoni A, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. <i>J Allergy Clin Immunol.</i> 2012;130(2):461-467.e5. doi:10.1016/j.jaci.2012.05.021</p>	<p>https://pubmed.ncbi.nlm.nih.gov/22743304/</p>
<p>Straumann A, Conus S, Degen L, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. <i>Clin Gastroenterol Hepatol.</i> 2011;9(5):400-409.e1. doi:10.1016/j.cgh.2011.01.017</p>	<p>https://pubmed.ncbi.nlm.nih.gov/21277394/</p>
<p>Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: A randomised, placebo-controlled, double-blind trial. <i>Gut.</i> 2010;59(1):21-30. doi:10.1136/gut.2009.178558</p>	<p>https://pubmed.ncbi.nlm.nih.gov/19828470/</p>

<p>Straumann A, Lucendo AJ, Miehke S, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. <i>Gastroenterology</i>. 2020;159(5):1672-1685.e5. doi:10.1053/j.gastro.2020.07.039</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32721437/</p>
<p>Wechsler ME, Fulkerson PC, Bochner BS, et al. Novel targeted therapies for eosinophilic disorders. <i>J Allergy Clin Immunol</i>. 2012;130(3):563-571. doi:10.1016/j.jaci.2012.07.027</p>	<p>https://pubmed.ncbi.nlm.nih.gov/22935585/</p>
<p>Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. <i>Lancet</i>. 2016;388(10039):31-44. doi:10.1016/S0140-6736(16)30307-5</p>	<p>https://pubmed.ncbi.nlm.nih.gov/27130691/</p>
<p>Zalewski A, Doerfler B, Krause A, Hirano I, Gonsalves N. Long-term outcomes of the six-food elimination diet and food reintroduction in a large cohort of adults with eosinophilic esophagitis [published online ahead of print, 2022 Oct 21]. <i>Am J Gastroenterol</i>. 2022;10.14309/ajg.0000000000001949. doi:10.14309/ajg.0000000000001949</p>	<p>https://pubmed.ncbi.nlm.nih.gov/35971213/</p>